Third Quarter 2022 Report
November 2, 2022
20/20's Multi-Cancer Early Detection Test featured in current issue of Prevention Magazine
A full-page advertisement for our OneTest for cancer appears in the November issue of Prevention magazine, available on newsstands everywhere. Over 3 million health enthusiasts are estimated to read this periodical each month. This is our first campaign using traditional print media to reach a large population. Additionally, an online article about these types of tests prepared jointly by our company and the Prevention staff has been posted to their website and can be downloaded here.

We believe that mass marketing will ultimately prove important for multi-cancer early detection (MCED) tests like ours. In August, a published study by a team of epidemiologists from the American Cancer Society suggested that most middle-aged adults might benefit from MCEDs. The ACS study noted that "screening of asymptomatic persons for cancer represents a bedrock of cancer control because it increases the probability of successful treatment. But the currently recommended screening tests only address about a third of all cancer deaths. New tests for the early detection of multiple cancers from a single blood draw may help detect a range of cancers with no current screening options.” 

The ACS study identified individuals over age 50, as well as those with a smoking history, high BMI, or a family history of any cancer, as those who “may benefit from enhanced cancer screening and prevention interventions.” 
CAP Accreditation and Clinical Lab License from California Received
In October 20/20's high complexity clinical laboratory, currently regulated under CLIA and the State of Maryland, received accreditation from the College of American Pathologists (CAP). CAP Accreditation covers a broad spectrum of laboratory disciplines and requires a scientifically rigorous set of requirements. Importantly it is a pre-requisite for a license from the California Department of Public Health to receive and process specimens from California residents, which was also received last month. Some experts estimate that as many as 50% of U.S. consumers who purchase healthcare products online are residents of California.
1st Test Launched from our Clinical Lab Innovation Accelerator
Australian diagnostics company Minomic announced last month that their lead product, MiCheck® Prostate, recorded its initial commercial sales in the US market.

MiCheck® Prostate is a blood test for patients with elevated PSA levels to assess the percentage risk of aggressive prostate cancer, helping avoid unnecessary biopsies. Each year, two million American men undergo highly invasive prostate biopsies to diagnose prostate cancer after an elevated Prostate-Specific Antigen (PSA) test result. A significant proportion of these biopsies are unnecessary, as the patient does not have cancer or has a low-grade cancer that requires monitoring rather than intervention.

The test is run out of 20/20's Clinical Lab Innovation Accelerator (CLIAx). Believed to be the first shared CLIA lab designed to help diagnostics start-ups more rapidly enter the U.S. market, CLIAx offers nearly 3,000 square feet of ready-to-use communal clinical laboratory space and testing equipment. Additionally, 20/20’s marketing and sales teams help promote the new tests introduced by CLIAx’s clients to the market segments in which 20/20 is currently active.
20/20 Ranks #131 on Inc.5000 list of America's Fastest Growing Private Companies
In August our company was ranked #131 across all industries and #3 among health products companies on the 2022 Inc. 5000 list of the fastest growing private companies in the United States. (We ranked #770 on the 2021 list.) These rankings are based on 3-year revenue growth which for us was largely attributable to pandemic related testing.
Nine Month Revenues Top $10 million, more than Double Amount from Same Period Last Year
For the 9-month period ending in September 20/20's revenue exceeded $10 million (unaudited) for all products compared to $3.8 million during the same period last year. Coronavirus associated testing in the first half of the year accounted for the bulk of these revenues. Test volume in the second half of 2022 has dropped considerably and is expected to remain low absent a year-end Covid surge in our region.
Crowdfunding Campaign Underway on Start Engine Closing Soon
20/20 current crowdfunding campaign on StartEngine will be ending soon. 20/20 is believed to be one of the first life science companies in America to successfully raise over $10 million through equity crowdfunding and we look forward to offering additional securities to our existing shareholders while welcoming new investors as well. All investors in this round can receive substantial discounts on current and future lab tests offered by our company.

Please visit our page on StartEngine to invest before our campaign ends.
You should read the Form C and Risks related to this offering before investing. This Reg CF offering will be made available through StartEngine Primary, LLC, member FINRA/SPIC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Company Webinar: Thur. Nov. 17, @12 noon ET
Join us on Nov. 17 at noon Eastern Time for an informational webinar for shareholders, prospective investors, and others interested in learning about our company and plans for 2023. Click here to register for the webinar
or contact for questions.

Our previous Quarterly Reports and Press Releases may be downloaded here:
Financial Reports
In order to maintain our Reg. A+ Qualification we are required to file Annual and Semiannual Reports with the U.S. Securities & Exchange Commission (SEC) that include Financial Statements (the Annual Statement must be audited). Those reports may be accessed by entering "20/20 GeneSystems, Inc." at or by contacting
Forward Looking Statements
This quarterly report to shareholders contains statements that do not relate to historical facts but are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can generally (although not always) be identified by their use of terms and phrases such as anticipate, appear, believe, continue, could, estimate, expect, indicate, intend, may, plan, possible, predict, project, pursue, will, would and other similar terms and phrases, as well as the use of the future tense. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the business of the Company, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control, including the risks described in our offering statements and reports under the heading “Risk Factors” as filed with the SEC. Actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this quarterly report to shareholders speak only as of the date hereof. Unless otherwise required by law, we undertake no obligation to publicly update or revise these forward-looking statements, whether because of new information, future events or otherwise.